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is procalcitonin ready for prime time?
New definitions of the human sepsis syndrome were pro-
posed a decade ago [1]. These definitions were needed in
order for clinicians to speak the same language, as well as
to identify and compare patient populations in clinical tri-
als. The nature and the importance of the host response to
the infectious process were central to these new defini-
tions and contrasted with previous definitions, which were
more microbiologically-oriented. The 1992 ACCP/SCCM
definitions were adopted by the majority of clinical inves-
tigators and allowed the stratification of patients with vari-
ous risks of death. However, many physicians would ad-
mit that the definitions remain imperfect and are not wide-
ly used at the bedside. Firstly, the concept of the systemic
inflammatory response syndrome (SIRS) has been chal-
lenged because of its poor specificity and also because
some patients may have clinical sepsis and yet lack two
SIRS criteria [2, 3]. SIRS is also the addition of a restrict-
ed number of signs that may not be relevant to an inflam-
matory process. Finally, a systemic pro-inflammatory re-
sponse has been difficult to demonstrate in septic patients
[4]. Secondly, the definition of the sepsis syndrome relies
on the documentation of an infection, which is not often
readily available at the time of admission to the emergen-
cy room or to the ICU. Thirdly, in contrast with many
acute and severe diseases such as myocardial infarction,
pancreatitis, renal and liver failure, etc., sepsis lacks (a)
specific biomarker(s). A useful biological marker of sepsis
should show a high diagnostic yield, be predictive for out-
come, easy to determine, robust and cheap. Similarly to
other ‘syndromes’ such as the acute respiratory distress
syndrome, an important difficulty to identify and study
biomarkers in sepsis is the heterogeneity of the patient
population and the lack of a clear-cut gold standard.
Several biomarkers of sepsis have been proposed, in-
cluding, for example, the percentage of circulating nonseg-
mented neutrophils (band forms), acute phase proteins
such as C-reactive protein and neopterin, cytokines (TNF,
IL-6) and chemokines (IL-8) [5, 6]. Whereas all of these
markers have shown some utility in detecting “septic
events,” they all lack specificity due to a significant over-
lap with levels measured in other systemic inflammatory
diseases. The challenge is to identify a biomarker of host
response that would be specific for (severe) infection or for
infection inducing organ dysfunction and/or shock. Elevat-
ed levels of procalcitonin were first described in 1993 in
“septic” pediatric patients [7]. In this seminal study, the au-
thors were able to differentiate children with sepsis from
those with localized bacterial infections or with severe vi-
ral infections using plasma procalcitonin measurements
[7]. Since then, nearly 100 investigations have evaluated
the diagnostic and prognostic yield of plasma procalcitonin
in different settings, including patients with neutropenia,
renal and hepatic failure, patients from the emergency
room and the ICU. The exact cellular and organ source for
the pro-hormone, its regulation and its relationship with
bacteria and bacterial products remain largely unknown.
In this issue of Intensive Care Medicine, Giamarollos-
Bourboulis et al. confirm the usefulness of measuring plas-
ma procalcitonin in identifying patients with severe sepsis
and septic shock [8]. Together with other investigators [9],
they however raise concerns as to whether this marker is
able to clearly differentiate SIRS patients from those with
sepsis. Differentiating these two patient populations is cer-
tainly the most challenging task. As indicated above, the
diagnosis of sepsis relies on the documentation of an infec-
tion in patients presenting with nonspecific systemic signs
such as tachycardia, tachypnea, leukocytosis or fever. The
potential risk for a misclassification of septic patients as
being “SIRS patients” because of unrecognized infections
or of patients as belonging to the “sepsis patient” group be-
cause of colonization rather than true infection is impor-
tant. The overlap of values of an infectious biomarker in
this situation is therefore very likely. This raises the possi-
bility that procalcitonin may actually be a more reliable
marker of sepsis that the ACCP/SCCM consensus confer-
ence criteria. The other possible explanation for these find-
ings is that procalcitonin reacts as an acute phase protein in
situations such as multiple trauma or cardiac surgery and
could explain higher “basal levels” in these patients. Se-
vere bacterial infection may only boost procalcitonin levels
in these patients “primed” with a systemic inflammatory
disorder. The diagnostic yield of such a marker is also
highly dependent on the pre-test probability. The best
yields will be obtained in a population with a high inci-
dence of sepsis, and the lowest if the marker is used as a
“screening test” in a group of patients with a low inci-
dence. Many authors would now admit that a “gray zone”
exists where procalcitonin levels falling in the range be-
tween 0.5 and 2 ng/ml are difficult to interpret. Levels
above 2 ng/ml are usually indicative of a bacterial infection
with a systemic inflammatory response, whereas levels be-
low 0.5 ng/ml generally rule out a bacterial infection as the
process responsible for signs of SIRS. It is important here
to stress that procalcitonin should not be used as the sole
marker in case of suspicion of sepsis, but rather be inte-
grated in the complex evaluation of the septic patient to-
gether with clinical, radiological and laboratory data.
Giamarollos-Bourboulis et al. make another crucial
point in the study presented in this issue [8]. They show
that the evolution of plasma procalcitonin levels with
time carries an important prognostic information. This
has been reported in several recent studies and may well
represent the “niche” for procalcitonin measurements in
our intensive care units [6, 10]. Like many other investi-
gators, they found that the initial procalcitonin level poor-
ly predicted the final outcome and loosely correlated with
the severity of the sepsis syndrome and the development
of multiple organ dysfunction. However, patients who do
well have a sharp decrease in their plasma procalcitonin
levels, usually crossing the 1 ng/ml threshold value with-
in 4 to 7 days [6]. In contrast, patients with an ultimately
fatal outcome show either a slow decrease or even an in-
crease in their plasma procalcitonin levels over the first
few days in the ICU. The prognostic value of daily mea-
surements of plasma procalcitonin appears superior to
that of C-reactive protein [10]. In the clinical arena, daily
measurement of procalcitonin may be used as a “red flag”
marker that the patient is not clearing the infection pro-
cess properly. Persistently elevated levels therefore may
trigger further investigations (bronchoalveolar lavage,
laparotomy, pleural tap, etc.) and possibly an adaptation
of therapy (surgery, antimicrobial therapy, etc.).
Laboratory measurements should only be performed if
they help in making decisions in patients and/or are useful
to follow the patient’s evolution. Despite abundant litera-
ture on procalcitonin, studies of the direct impact of its
measurement on the outcome of patients unfortunately are
lacking. For example, studies could be designed in which
patients with a fast decrease in procalcitonin levels receive
a shorter duration of antibiotic therapy, or even have the
antibiotics stopped if procalcitonin is two times below a
threshold value. Alternatively, it could be studied whether
the knowledge of procalcitonin levels can influence the
clinician to trigger new investigations. Sepsis definitions
are currently being rediscussed in a new consensus confer-
ence. A major issue will be whether or not to introduce (a)
biomarker(s) in the new set of definitions. Clearly, addi-
tional fundamental and clinical investigations are needed
in order to convince clinicians to use procalcitonin plasma
levels on a regular basis as an aid for the care of the criti-
cally ill patient presenting with a suspicion of sepsis.
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